Pulling SEC filings + quote and writing the call…
AXSM
Axsome Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.90 EPS, $224M rev
Last earnings +8.3% on 2026-05-04
$252.64
▲ +0.85%$250.50▲ +146.34%
over 1Y
L $100.39EODHDH $255.17
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+0.9%
1W-1.3%
1M+10.5%
3M+57.7%
YTD+40.2%
1Y+146.3%
Buy
Conviction
Horizon
Long (>12mo)
Street · 27 analysts
Buy
CNS biopharma scaling fast — revenue +65.5% to $638M across three launched drugs, with losses narrowing and a deep pipeline.
Axsome has transitioned from a clinical-stage story into a commercial-stage CNS company with real, accelerating revenue. FY2025 revenue grew 65.5% to $638M behind three FDA-approved products — AUVELITY (the first oral NMDA antagonist for major depressive disorder), SUNOSI (excessive daytime sleepiness), and the newly launched SYMBRAVO (acute migraine). Crucially, the losses are shrinking even as the company invests: net loss narrowed 36% to -$183M and the operating loss improved 41% to -$167M, while operating cash burn fell to -$93.4M. That is the right trajectory for a scaling specialty-pharma launch.
Sources: SEC EDGAR (CIK 0001579428, latest 10-Q filed 2026-05-04) · EODHD · analysis by claude-code · as of 6/21/2026, 8:46:33 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.